Monomeric antibodies, primarily found in the IgG, IgD, and IgE isotypes, are single-unit structures composed of two heavy chains and two light chains connected by disulfide bonds. In contrast, other antibody classes like IgA and IgM exist as oligomeric complexes formed by multiple antibody units. This structural simplicity makes monomeric antibodies essential for therapeutic applications, as they provide a stable and predictable framework for drug development.
Functions of Monomeric Antibodies in the Immune System
Neutralization: They bind to pathogens or toxins, preventing their interaction with host cells.
Opsonization: By coating pathogens, monomeric antibodies enhance recognition and phagocytosis by immune cells like macrophages.
Complement Activation: IgG antibodies, for instance, trigger the complement cascade, a series of immune responses that lead to pathogen lysis.
Allergen Response: IgE antibodies bind allergens and trigger histamine release from mast cells, mediating allergic reactions.
The Importance of Monomeric Antibodies in Biopharmaceuticals
Most proteins, including antibodies, are prone to polymerization—a process where multiple molecules aggregate, forming dimers, trimers, or larger complexes. While polymer formation can occur naturally during production, storage, or transport, it introduces several challenges in therapeutic contexts. For monoclonal antibodies (mAbs), minimizing polymer content is critical for two primary reasons:
Maintaining Drug Efficacy: Polymerization can reduce the bioactivity of antibodies, making treatments less effective.
Reducing Immunogenicity: Polymers can increase the immune response in patients, potentially leading to adverse effects. The immunogenicity of polymers often correlates with the repetitiveness of surface antigenic epitopes and their size.
In vivo studies have shown that polymer properties, such as their natural structure and size, strongly influence their immunogenic potential. Therefore, controlling polymer levels during antibody production is essential for ensuring therapeutic safety and effectiveness.
Related: What is Antibody Glycosylation?
Mechanisms of Polymer Formation in Antibodies
Polymer formation in antibodies involves a series of structural changes:
Unfolding and Misfolding: The natural structure of an antibody may be disrupted, exposing hydrophobic "hot spots" on amino acid sequences that promote aggregation.
Reversible Self-Polymerization: Initial aggregation may be reversible, but further conformational changes can lead to irreversible polymer formation.
Expansion and Interaction: Subsequent addition of monomers and interactions between polymers can result in larger soluble or insoluble aggregates.
These processes are influenced by strong non-covalent forces, such as hydrophobic interactions, which drive the aggregation of exposed "hot spots." Though modifying these sequences genetically can potentially reduce polymerization, predicting the precise locations of these sites remains challenging.
Biointron can help in your therapeutic antibody production. We provide services for HTP Recombinant Antibody Production, Bispecific Antibody Production, Large Scale Antibody Production, Afucosylated Antibody Expression, and RushMab™ - Small Scale Expression Packages. Learn more here: https://www.biointron.com/services/.
DOI: 10.3389/fbioe.2022.856049Antibodies have become essential tools for the diagnosis and treatment of numerous human diseases. However, non-human antibodies, such as those derived from murine sources, often provoke human anti-mouse antibody (HAMA) responses. This immunogenicity leads to rapid clea
In therapeutic antibody development, achieving high-affinity antigen binding is central to improving drug efficacy, durability, and safety.Biointron’s High-Throughput Fully Human Antibody Discovery service is designed to meet this need by integrating advanced screening and engineering technol
I. Introduction to Hybridoma TechnologyHybridoma technology, developed by Köhler and Milstein in 1975, is a foundational method for producing monoclonal antibodies (mAbs). The approach involves fusing antibody-producing B lymphocytes with immortal myeloma cells to form hybridoma cells. These hybrid
Introduction to Monoclonal Antibody Discovery Monoclonal antibodies (mAbs) are one of the most successful classes of biologic drugs on the global pharmaceutical market. Since the approval of Orthoclone OKT3 in 1986, over 100 mAbs have been approved by the U.S. FDA for indications incl
ScientistとScience Exchangeとのご利用可能です。
